Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial

BackgroundThe skeleton is a preferred site for prostate cancer metastasis, and once metastases occur, the disease becomes incurable. Increasing evidence indicates the prognostic value of skeletal-related parameters, but remains controversial.ObjectiveTo perform a systematic review of the existing li...

Full description

Bibliographic Details
Main Authors: Tongyu Tong, Hanqi Lei, Yupeng Guan, Xiangwei Yang, Guolong Liao, Yamei Li, Donggen Jiang, Jun Pang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.586192/full
_version_ 1818192527263531008
author Tongyu Tong
Hanqi Lei
Yupeng Guan
Xiangwei Yang
Guolong Liao
Yamei Li
Donggen Jiang
Jun Pang
author_facet Tongyu Tong
Hanqi Lei
Yupeng Guan
Xiangwei Yang
Guolong Liao
Yamei Li
Donggen Jiang
Jun Pang
author_sort Tongyu Tong
collection DOAJ
description BackgroundThe skeleton is a preferred site for prostate cancer metastasis, and once metastases occur, the disease becomes incurable. Increasing evidence indicates the prognostic value of skeletal-related parameters, but remains controversial.ObjectiveTo perform a systematic review of the existing literature on assessing the prognostic value of alkaline phosphatase (ALP), bone-specific alkaline phosphatase (BSAP), urinary N-telopeptide (uNTx), bone scan index (BSI), and Brief Pain Inventory Short Form (BPI-SF) score in castration-resistant prostate cancer (CRPC) patients with skeleton metastasis.Evidence AcquisitionPubMed, Web of Science, Cochrane Library, Medline, OVID, and Embase between 2010 and 2019 were reviewed. Key terms included randomized trials, prostate cancer, alkaline phosphatase, bone-specific alkaline phosphatase, urinary N-telopeptide, bone scan index, and Brief Pain Inventory Short Form. Data were collected, checked, and analyzed from December 2019 to March 2020. Hazard ratios (HRs) and overall survival (OS) were extracted to estimate the relationship between the above parameters and OS in patients with metastatic prostate cancer (mPCa).Evidence SynthesisA total of 1,055 studies were identified via initial screening, including 1,032 from database research and 23 from other sources. After deduplication, 164 records were further excluded according to titles and abstracts. The remaining 36 potential articles were carefully screened. In the end, 15 eligible studies syntheses, which were published between 2010 and 2019, comprised data for a total of 11,378 patients, whose mean age ranged from 66 to 72 years. The sample size ranged from 82 to 1,901 patients. And the median follow-up time ranged from 24 to 55 months. Based on 15 randomized controlled trials published between 2010 and 2019, higher ALP levels (HR = 1.60, 95% CI: 1.38–1.87 P < 0.001), higher BSAP levels (HR = 1.31, 95% CI: 1.11–1.54 P = 0.001), higher uNTx levels (HR = 1.40, 95% CI: 1.29–1.52 P < 0.001), BSI progression (HR = 1.18, 95% CI: 1.08–1.29 P < 0.001), and higher BPI-SF score (HR = 1.47, 95% CI: 1.35–1.61 P < 0.001) had an association with inferior OS.ConclusionsHigher levels of ALP/BSAP and uNTx, a higher BPI-SF score, and progression of BSI predict inferior OS in patients with mCRPC. More randomized control trials are needed to investigate the promising value of these parameters.
first_indexed 2024-12-12T00:31:55Z
format Article
id doaj.art-2dc15afd48bd434493c34da2060c4506
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-12-12T00:31:55Z
publishDate 2020-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-2dc15afd48bd434493c34da2060c45062022-12-22T00:44:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-11-011010.3389/fonc.2020.586192586192Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled TrialTongyu TongHanqi LeiYupeng GuanXiangwei YangGuolong LiaoYamei LiDonggen JiangJun PangBackgroundThe skeleton is a preferred site for prostate cancer metastasis, and once metastases occur, the disease becomes incurable. Increasing evidence indicates the prognostic value of skeletal-related parameters, but remains controversial.ObjectiveTo perform a systematic review of the existing literature on assessing the prognostic value of alkaline phosphatase (ALP), bone-specific alkaline phosphatase (BSAP), urinary N-telopeptide (uNTx), bone scan index (BSI), and Brief Pain Inventory Short Form (BPI-SF) score in castration-resistant prostate cancer (CRPC) patients with skeleton metastasis.Evidence AcquisitionPubMed, Web of Science, Cochrane Library, Medline, OVID, and Embase between 2010 and 2019 were reviewed. Key terms included randomized trials, prostate cancer, alkaline phosphatase, bone-specific alkaline phosphatase, urinary N-telopeptide, bone scan index, and Brief Pain Inventory Short Form. Data were collected, checked, and analyzed from December 2019 to March 2020. Hazard ratios (HRs) and overall survival (OS) were extracted to estimate the relationship between the above parameters and OS in patients with metastatic prostate cancer (mPCa).Evidence SynthesisA total of 1,055 studies were identified via initial screening, including 1,032 from database research and 23 from other sources. After deduplication, 164 records were further excluded according to titles and abstracts. The remaining 36 potential articles were carefully screened. In the end, 15 eligible studies syntheses, which were published between 2010 and 2019, comprised data for a total of 11,378 patients, whose mean age ranged from 66 to 72 years. The sample size ranged from 82 to 1,901 patients. And the median follow-up time ranged from 24 to 55 months. Based on 15 randomized controlled trials published between 2010 and 2019, higher ALP levels (HR = 1.60, 95% CI: 1.38–1.87 P < 0.001), higher BSAP levels (HR = 1.31, 95% CI: 1.11–1.54 P = 0.001), higher uNTx levels (HR = 1.40, 95% CI: 1.29–1.52 P < 0.001), BSI progression (HR = 1.18, 95% CI: 1.08–1.29 P < 0.001), and higher BPI-SF score (HR = 1.47, 95% CI: 1.35–1.61 P < 0.001) had an association with inferior OS.ConclusionsHigher levels of ALP/BSAP and uNTx, a higher BPI-SF score, and progression of BSI predict inferior OS in patients with mCRPC. More randomized control trials are needed to investigate the promising value of these parameters.https://www.frontiersin.org/articles/10.3389/fonc.2020.586192/fullmetastatic castration-resistant prostate cancerskeletal-related parametersoverall survivalprognosismeta-analysis
spellingShingle Tongyu Tong
Hanqi Lei
Yupeng Guan
Xiangwei Yang
Guolong Liao
Yamei Li
Donggen Jiang
Jun Pang
Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial
Frontiers in Oncology
metastatic castration-resistant prostate cancer
skeletal-related parameters
overall survival
prognosis
meta-analysis
title Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial
title_full Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial
title_fullStr Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial
title_full_unstemmed Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial
title_short Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial
title_sort revealing prognostic value of skeletal related parameters in metastatic castration resistant prostate cancer on overall survival a systematic review and meta analysis of randomized controlled trial
topic metastatic castration-resistant prostate cancer
skeletal-related parameters
overall survival
prognosis
meta-analysis
url https://www.frontiersin.org/articles/10.3389/fonc.2020.586192/full
work_keys_str_mv AT tongyutong revealingprognosticvalueofskeletalrelatedparametersinmetastaticcastrationresistantprostatecanceronoverallsurvivalasystematicreviewandmetaanalysisofrandomizedcontrolledtrial
AT hanqilei revealingprognosticvalueofskeletalrelatedparametersinmetastaticcastrationresistantprostatecanceronoverallsurvivalasystematicreviewandmetaanalysisofrandomizedcontrolledtrial
AT yupengguan revealingprognosticvalueofskeletalrelatedparametersinmetastaticcastrationresistantprostatecanceronoverallsurvivalasystematicreviewandmetaanalysisofrandomizedcontrolledtrial
AT xiangweiyang revealingprognosticvalueofskeletalrelatedparametersinmetastaticcastrationresistantprostatecanceronoverallsurvivalasystematicreviewandmetaanalysisofrandomizedcontrolledtrial
AT guolongliao revealingprognosticvalueofskeletalrelatedparametersinmetastaticcastrationresistantprostatecanceronoverallsurvivalasystematicreviewandmetaanalysisofrandomizedcontrolledtrial
AT yameili revealingprognosticvalueofskeletalrelatedparametersinmetastaticcastrationresistantprostatecanceronoverallsurvivalasystematicreviewandmetaanalysisofrandomizedcontrolledtrial
AT donggenjiang revealingprognosticvalueofskeletalrelatedparametersinmetastaticcastrationresistantprostatecanceronoverallsurvivalasystematicreviewandmetaanalysisofrandomizedcontrolledtrial
AT junpang revealingprognosticvalueofskeletalrelatedparametersinmetastaticcastrationresistantprostatecanceronoverallsurvivalasystematicreviewandmetaanalysisofrandomizedcontrolledtrial